# Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2

Study · id `cardio:ct-nct02777593` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02777593](<https://clinicaltrials.gov/study/NCT02777593>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT02777593

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 250 participants.

## Technical summary

Registry record NCT02777593. Non-randomized; no masking; primary purpose treatment. Start 2016-09-06 (actual); primary completion 2021-04-12 (actual). Results posted on 2022-11-22.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 250 participants (enrolled count; ClinicalTrials.gov record NCT02777593, source copy `cardio:ctgov-nct02777593-2026-09-10`, retrieved 2026-11-18)
- Started: 2016-09-06 (actual) (ClinicalTrials.gov record NCT02777593, source copy `cardio:ctgov-nct02777593-2026-09-10`, retrieved 2026-11-18)
- Primary completion: 2021-04-12 (actual) (ClinicalTrials.gov record NCT02777593, source copy `cardio:ctgov-nct02777593-2026-09-10`, retrieved 2026-11-18)
- Completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT02777593, source copy `cardio:ctgov-nct02777593-2026-09-10`, retrieved 2026-11-18)
- Results first posted: 2022-11-22 (ClinicalTrials.gov record NCT02777593, source copy `cardio:ctgov-nct02777593-2026-09-10`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT02777593, source copy `cardio:ctgov-nct02777593-2026-09-10`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02777593-2026-09-10`, retrieved 2026-11-18)

## The registry's words

- Brief title: Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
- Acronym: SSB 11-02
- Condition: Aortic Aneurysm, Thoracic
- Condition: Aorta; Lesion
- Intervention (Device): GORE® TAG® Thoracic Branch Endoprosthesis
- Lead sponsor: W.L.Gore & Associates
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic aneurysm (`cardio:aortic-aneurysm`)
- Registry condition terms include this condition: Thoracic aortic aneurysm (`cardio:thoracic-aortic-aneurysm`)
- Registry lists this organization as the lead sponsor: W.L.Gore & Associates (`cardio:org-w-l-gore-associates`)

## Provenance

Content hash: 3053c7e4c802eef7aff50ee47bfeafc406d6b6e55c4a56953a0ff6b4fc7bb324
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
